Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: Outcomes from TECOS. 由 Engel, S, Suryawanshi, S, Stevens, S, Josse, R, Cornel, J, Jakuboniene, N, Riefflin, A, Tankova, T, Wainstein, J, Peterson, E, Holman, R, TECOS Study Group

Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. 由 Cornel, J, Bakris, G, Stevens, S, Alvarsson, M, Bax, W, Chuang, L, Engel, S, Lopes, R, McGuire, D, Riefflin, A, Rodbard, H, Sinay, I, Tankova, T, Wainstein, J, Peterson, E, Holman, R

Pancreatic safety of sitagliptin in the TECOS Study. 由 Buse, J, Bethel, M, Green, J, Stevens, S, Lokhnygina, Y, Aschner, P, Grado, C, Tankova, T, Wainstein, J, Josse, R, Lachin, J, Engel, S, Patel, K, Peterson, E, Holman, R, TECOS Study Group